Evolus/$EOLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolus
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Ticker
$EOLS
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
372
Website
Evolus Metrics
BasicAdvanced
$614M
-
-$0.89
0.98
-
Price and volume
Market cap
$614M
Beta
0.98
52-week high
$17.12
52-week low
$8.67
Average daily volume
920K
Financial strength
Current ratio
2.342
Quick ratio
2.051
Long term debt to equity
-1,941.763
Total debt to equity
-1,971.548
Interest coverage (TTM)
-1.78%
Profitability
EBITDA (TTM)
-26.698
Gross margin (TTM)
68.41%
Net profit margin (TTM)
-20.40%
Operating margin (TTM)
-11.95%
Effective tax rate (TTM)
-1.24%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
-9.36%
Return on equity (TTM)
-949.46%
Valuation
Price to revenue (TTM)
2.188
Price to book
-93
Price to tangible book (TTM)
-93
Price to free cash flow (TTM)
-20.852
Free cash flow yield (TTM)
-4.80%
Free cash flow per share (TTM)
-45.70%
Growth
Revenue change (TTM)
25.38%
Earnings per share change (TTM)
-14.84%
3-year revenue growth (CAGR)
31.43%
3-year earnings per share growth (CAGR)
-12.00%
What the Analysts think about Evolus
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Bulls say / Bears say
Evolus reported its first-ever adjusted quarterly profit in Q2 2024, driven by strong sales of its Botox competitor, Jeuveau, indicating successful market penetration and operational efficiency. (reuters.com)
The company has captured 13% of the U.S. neuromodulator market within five years, showcasing its ability to compete effectively against established players. (finviz.com)
Evolus plans to diversify its product line with the upcoming launch of Evolysse, a premium dermal filler, potentially adding approximately $200 million to its revenue over time. (finviz.com)
Evolus reported a quarterly adjusted loss of 15 cents per share for Q1 2025, indicating ongoing challenges in achieving consistent profitability. (tradingview.com)
The company's debt-to-equity ratio stands at 23.54, significantly higher than industry norms, suggesting potential financial strain and increased risk. (nasdaq.com)
Evolus's return on equity (ROE) is -119.02%, indicating difficulties in efficiently utilizing equity capital and delivering satisfactory returns to shareholders. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Evolus Financial Performance
Revenues and expenses
Evolus Earnings Performance
Company profitability
Evolus News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evolus stock?
Evolus (EOLS) has a market cap of $614M as of July 28, 2025.
What is the P/E ratio for Evolus stock?
The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of July 28, 2025.
Does Evolus stock pay dividends?
No, Evolus (EOLS) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Evolus dividend payment date?
Evolus (EOLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolus?
Evolus (EOLS) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.